Healthcare data analytics company Health Catalyst (NASDAQ: HCAT) will report earnings this Monday after market hours. Here’s what you need to know.
Health Catalyst met analysts’ revenue expectations last quarter, reporting revenue of $80.72 million, up 6.3% year over year. This was a slower quarter for the company, with revenue forecasts for the full year coming in significantly below analyst expectations and revenue forecasts for the next quarter coming in significantly below analysts’ expectations.
Is Health Catalyst a Profitable Buy or Sell? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts expect Health Catalyst’s revenue to decline 1.8% year over year to $75.01 million, a reversal from the 3.5% increase recorded in the same quarter last year. Adjusted earnings are expected to be $0.07 per share.
Analysts covering the company have generally reconfirmed their estimates over the past 30 days, suggesting they expect the company to stay the course before reporting profits. Health Catalyst has only missed Wall Street revenue estimates once in the past two years, beating expectations by an average of 0.6%.
Looking at Health Catalyst’s peers in the data analytics segment, some have already released their third quarter results, giving us an idea of ​​what we can expect. Strategy delivered year-over-year revenue growth of 10.9%, beating analysts’ expectations of 9.1%, and Palantir Technologies reported revenue up 62.8%, beating estimates by 8%. The strategy rose 6% following the results while Palantir Technologies fell 8.1%.
Read our full analysis of Strategy’s results here and Palantir Technologies’ results here.
Investors in the data analytics segment have had a firm grip on profits, with stock prices remaining stable over the past month. Health Catalyst is up 6.8% in the same period and headed for profits with an average analyst price target of $4.33 (compared to the current stock price of $2.83).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense, provided the price is right. Luckily, we found one, a low-priced stock that generates free cash flow AND buys back shares. Click here to claim your free special report on a fallen angel growth story already recovering from a setback.
StockStory is growing and recruiting for equity analyst and marketing positions. Are you a 0 to 1 builder passionate about markets and AI? View open roles here.
